Platinum-resistant cancer treatment
AssigneeBTG International Limited
InventorUdai Banerji
Life of this patent
Estimating the term…
Abstract
A compound of formula I or a pharmaceutically acceptable salt or ester thereof is provided for the treatment of cancer wherein (i) the cancer is one that has the characteristic of being a type prone to being or becoming refractory or resistant to platinum drug based therapy and (ii) the treatment is with a dose of between 1 mg/m2 and 30 mg/m2 of compound per patient body surface area per administration. Method of treatment and novel dosage forms are also provided. Particularly treated arc ovarian cancers, particularly those expressing a-folate receptors, including epithelial ovarian, fallopian tube or peritoneal cancer.
Claims34
A method of treating ovarian cancer that is platinum refractory or resistant in a patient in need thereof comprising administering to the patient in need thereof a compound of formula I
- or a pharmaceutically acceptable salt or ester thereof wherein
- (i) the treatment is with a dose of from 8 mg/m2 to 15 mg/m2 of compound per patient body surface area per administration, and
- (ii) the treatment is administered by infusions of the dose, wherein the infusions are spaced from 10 to 21 days apart.
A method of treating ovarian cancer that is platinum refractory or resistant in a patient in need thereof comprising administering to the patient in need thereof a trisodium salt of formula II:
- wherein
- (i) the treatment is with a dose of from 8 mg/m2 to 15 mg/m2 of compound per patient body surface area per administration, and
- (ii) the treatment is administered by infusions of the dose, wherein the infusions are spaced from 10 to 21 days apart.
A method of treating ovarian cancer that is platinum refractory or resistant in a patient in need thereof comprising administering to the patient in need thereof a compound of formula I
- or a pharmaceutically acceptable salt or ester thereof wherein
- (i) the treatment is with a dose of 12 mg/m2 of compound per patient body surface area per administration, and
- (ii) the treatment is administered by infusions of the dose, wherein the infusions are spaced from 10 to 21 days apart.
Dependencies are inferred from the claim text.